Cytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and
response. Of 57 putatively functional human CYPs only about a dozen enzymes, belonging …

Interindividual variability in drug response is a major clinical problem. Polymedication and
genetic polymorphisms modulating drug-metabolising enzyme activities (cytochromes P450 …

Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …

Importance Data are limited regarding the association betweenCYP2C19genetic variants
and clinical outcomes of patients with minor stroke or transient ischemic attack treated with …

Context The US Food and Drug Administration recently recommended that CYP2C19
genotyping be considered prior to prescribing clopidogrel, but the American Heart …

Over the past decade, pharmacogenetic testing has emerged in clinical practice to guide
selected cardiovascular therapies. The most common implementation in practice is …

BACKGROUND Several studies have examined associations between genetic variants and
the risk of gestational diabetes mellitus (GDM). However, inferences from these studies were …

Phenoconversion is a phenomenon that converts genotypic extensive metabolizers (EM s)
into phenotypic poor metabolizers (PM s) of drugs, thereby modifying their clinical response …

Introduction: Variability of drug response is an important consideration in clinical medicine. A
major determinant of drug response variability is hepatic cytochrome P450 oxidase …

Interindividual differences in drug disposition are important causes for adverse drug
reactions and lack of drug response. The majority of phase I and phase II drug-metabolizing …